Results 91 to 100 of about 7,686 (201)

A retrospective observational study to determine baseline characteristics and early prescribing patterns for patients receiving Alirocumab in UK clinical practice [PDF]

, 2019
Background Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) and has been previously shown, in the phase III ODYSSEY clinical trial program, to provide significant lowering of lowdensity lipoprotein
BG Nordestgaard, C Baigent, CP Cannon, EM Roth, GG Schwartz, J Armitage, JC Defesche, JJ Kastelein, M Kohli, M Weinreich, ML Hartgers, MS Sabatine, S Glerup   +12 more
core   +4 more sources

Evolocumab for early reduction of LDL-C levels in patients with acute ischemic stroke: a randomized controlled trial

Frontiers in Neurology
BackgroundLow-density lipoprotein cholesterol (LDL-C) has been determined as an established risk factor for acute ischemic stroke (AIS). Despite the recommendation for in-hospital initiation of high-intensity statin therapy in AIS patients, achieving the
Xiaohui Qiu, Yeyuan Liang, Yunfei Wei, Mengru Lu, Yujia Mei, Shiting Tang, Jian Tang, Jinyu Liang, Junli Liang   +8 more
doaj   +1 more source

Miscellanea. Folyóirat-referátumok. Könyvismertetés [PDF]

, 2016
Esetismertetés. Ultrahangos és szcintigráfiás eltérések pajzsmirigy- hemiagenesisben szenvedő gyermeknél: egy ritka betegség esete (Ultrasonographic and scintigraphic findings of thyroid hemiagenesis in a child: report of a rare male case)
Apor, Péter, Fischer, Tamás, Gáspárdy, Géza, Jakobovits, Antal, Nagy, László Béla, Schneider, Imre, Ábel, Tatjána   +6 more
core   +1 more source

Asia–Pacific Real-World Evolocumab Use, LDL-C Reduction, Physician Goals, and Patient Perceptions: HALES Observational Study

Cardiology and Therapy
Introduction Real-world data are needed to understand the effectiveness of new therapeutic options for low-density lipoprotein cholesterol (LDL-C) reduction in Asia–Pacific clinical practice.
Hung-Fat Tse, Hung-Yu Chang, David Colquhoun, Jung-Sun Kim, Kian Keong Poh, Karam Kostner, Pisit Hutayanon, Meejin Cho, Jeff Lange, Kamlanathan Kodiappan, Saikiran Leekha   +10 more
doaj   +1 more source

Measurement of low‐density lipoprotein cholesterol levels in primary and secondary prevention patients: Insights from the PALM registry [PDF]

, 2018
Background The 2013 American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults recommended testing low-density lipoprotein cholesterol ( LDL -C) to ...
Goldberg, Anne C, Lee, L. Veronica, Li, Shuang, Louie, Michael J, Lowenstern, Angela M, Navar, Ann Marie, Peterson, Eric D, Robinson, Jennifer G, Roger, Veronique L, Virani, Salim S, Wang, Tracy Y, Wilson, Peter W.F.   +11 more
core   +2 more sources

Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: An open label, non-randomized, controlled study [PDF]

, 2018
Additional file 1: Table S1. Detailed baseline characteristics for participants in the continuous care intervention (CCI) and usual care (UC ...
Ballard, Kevin D, Bhanpuri, Nasir H, Campbell, Wayne W, Hallberg, Sarah J, McCarter, James P, McKenzie, Amy L, Phinney, Stephen D, Volek, Jeff S, Williams, Paul T   +8 more
core   +4 more sources

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction

Vascular Health and Risk Management, 2016
Courtney A Henry, Ronald A Lyon, Hua Ling Department of Pharmacy Practice, School of Pharmacy, Hampton University, Hampton, VA, USA Abstract: Multiple categories of medications have been developed to manage lipid profiles and reduce the risk of ...
Henry CA, Lyon RA, Ling H
doaj  

Cardiovascular Paradigms: Time for Reappraisal [PDF]

, 2017
While much progress has been made in prevention and treatment over the last 60 years (though not as much as expected), the current paradigm of cardiovascular diseases (CVD) is now facing its most serious ...
Heitor Reis, Antonio
core  

Análisis de las controversias en los niveles de colesterol-LDL como indicador de riesgo cardiovascular [PDF]

, 2018
[ES] Objetivo: analizar las controversias existentes entre las guías de práctica clínica actuales y esclarecer qué recomendaciones pueden estar mejor fundamentadas en evidencia sólida y cuales pueden tener evidencia más débil.
Zubiaur Zamacola, Jon
core  

Impact of In-Hospital PCSK9 Inhibition on Myocardial Inflammation After Myocardial Infarction

JACC: Basic to Translational Science
Summary: In a randomized trial with 55 participants from the EVACS (Evolocumab in Acute Coronary Syndrome) trials, patients with non–ST-segment elevation myocardial infarction (MI) or ST-segment elevation MI received a single dose of evolocumab or ...
Efthymios Ziogos, MD, Tarek Harb, MD, Ines Valenta, MD, Michael A. Vavuranakis, MD, PhD, Palmer L. Foran, BS, Marlene S. Williams, MD, Michael J. Blaha, MD, MPH, Allison G. Hays, MD, Steven R. Jones, MD, Thomas H. Schindler, MD, Steven P. Schulman, MD, Gary Gerstenblith, MD, Thorsten M. Leucker, MD, PhD   +12 more
doaj   +1 more source